In cohort A part 1 of MAHOGANY, patients with HER2 IHC3+ and PD-L1-positive GEA received the chemotherapy-free regimen of margetuximab and retifanlimab, and most patients (78%) had tumor shrinkage at first scan. The gene discussed is ERBB2; the disease is neoplasm.